Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Article

Version

Accepted version

Publication date

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/194643

Genomics and epigenomics of substance use disorders: An introduction

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Substance use disorders (SUD) are common conditions around theworld, with important health and societal impacts, particularly inthe burden of disease (disability-adjusted life years) (Whiteford, Fer-rari, Degenhardt, Feigin, & Vos, 2015). The Global Burden of DiseaseStudy estimated the global number of cases for SUD for several sub-stances as follows: 94.8 million for alcohol, 17.2 million for amphet-amine, 15.5 million for opioids, and 13.1 million for cannabis(Whiteford, 2015). In the United States, the lifetime and 12-monthprevalences of SUD were 9.9% and 3.9%, respectively (Grantet al., 2016). In addition, polysubstance use is an important challengein the field of addiction research (Whiteford et al., 2015).

Subject (English)

Citation

Citation

CORMAND RIFÀ, Bru, et al. Genomics and epigenomics of substance use disorders: An introduction. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2021. Vol. 186, num. 3, pags. 125-127. ISSN 1552-4841. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/194643

Export metadata

JSON - METS

Share record